Harvard Bioscience, Inc. (HBIO) financial statements and ratios from SEC XBRL: revenue $86.55M (TTM), net margin -65.5%, revenue growth 11.1% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $86.55M |
| Net Margin | -65.5% |
| Revenue Growth (YoY) | 11.1% |
| EPS Growth (YoY) | 1180.0% |
| FCF Growth (YoY) | -113.6% |
| EV / EBITDA | 122.7 |
| Price / Book | 21.50 |
| Price / Sales | 1.82 |
| FCF Yield | -0.7% |
| DCF Value (model) | $1.24 |
| DCF Upside vs Price | -83.6% |
| Altman Z-Score | -1.22 (distress) |
| Piotroski F-Score | 4/9 |
| Sector P/E (Technology) | 33.9 |
HBIO overview · HBIO earnings · HBIO KPIs · HBIO investor relations · HBIO ownership · HBIO peers · HBIO filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.